

Post-Market Surveillance of Medical Devices Using AI

Abstract:

Artificial intelligence (AI) has emerged as a transformative tool in post-market surveillance (PMS) for monitoring the safety and performance of medical products. This article explores the role of AI in optimizing PMS practices, focusing on its applications in signal detection, risk assessment, and regulatory compliance. By harnessing machine learning algorithms and big data analytics, AI facilitates the automated analysis of real-world evidence, including patient outcomes data, adverse event reports, and electronic health records. Through pattern recognition and anomaly detection, AI algorithms enable the early identification of potential safety issues and facilitate timely interventions to mitigate risks. Moreover, AI-driven PMS systems enhance regulatory oversight by providing regulators with comprehensive and actionable insights into product safety profiles and emerging trends. However, concerns regarding data privacy, algorithm bias, and interpretability underscore the need for transparent and ethically responsible AI deployment in PMS frameworks.

Keywords: PMS (Post-Market Surveillance), Artificial intelligence, Medical devices, Healthcare

1. Introduction:

1.1. Background on Post-Market Surveillance (PMS):

Post-Market Surveillance (PMS) is an essential component of the regulatory framework for medical devices and pharmaceuticals. Its purpose is to guarantee the continued safety and effectiveness of a product once it has been made available to the market[1]. This procedure entails the methodical gathering, examination, and understanding of data concerning the effectiveness and negative occurrences of these items in actual environments[2]. Unlike pre-market evaluations, which are carried out in controlled settings with specific populations, post-

market surveillance (PMS) focuses on assessing the impact of the product on a wider and more varied population over a longer duration[3,77,78,79,80]. The objective is to detect any unanticipated hazards, unfavorable responses, or any enhancements that could augment patient safety and product efficacy. Regulatory authorities, such as the FDA in the United States and the EMA in Europe, enforce extensive Post-Market Surveillance (PMS) programs, which necessitate producers to regularly provide reports and updates[3]. These programs frequently involve actions like as reporting adverse events, conducting post-market clinical follow-up studies, maintaining registries, and preparing periodic safety update reports (PSURs)[3]. The collected data assist regulatory bodies in making well-informed judgments on product recalls, adjustments, or market withdrawals[4]. Technological progress, such as the development of big data analytics and real-time monitoring systems, has greatly improved the powers of PMS, allowing for more proactive and prompt interventions[4]. The healthcare sector strives to cultivate a culture of ongoing enhancement by adhering to rigorous PMS (Post-Market Surveillance)[4]. This practice guarantees the safety and efficacy of medical products throughout their lifespan, thereby safeguarding public health[4]. Post-Market Surveillance (PMS) plays a crucial role in guaranteeing the continuous safety and effectiveness of medical products[5].




Figure 1 PMS System

Post-market surveillance entails the ongoing monitoring of a device's performance after it has been made available to the public[5]. This process gathers crucial data that aids in the identification of potential faults that may not have been apparent during pre-market assessments. Product monitoring systems (PMS) allow manufacturers and regulatory agencies to swiftly identify and manage adverse occurrences, device failures, and other safety concerns[6]. Adopting a proactive strategy is crucial in preserving public health as it effectively reduces the hazards linked to medical equipment. PMS facilitates the gathering of empirical data, which can result in enhancements to device architecture and performance, ultimately improving patient outcomes as a whole[6]. Regulatory compliance is an important factor, as health authorities worldwide often need continuous monitoring to ensure that devices consistently fulfil strict safety and performance criteria throughout their lifespan[7]. In essence, PMS cultivates a culture of ongoing enhancement and attentiveness, strengthening the confidence of healthcare personnel and patients in medical technologies. Conventional approaches to post-market monitoring (PMS) mainly consist of spontaneous reporting systems, periodic safety update reports (PSURs), and registry data. Spontaneous reporting systems, such as the FDA's MedWatch and the European Medicines Agency's EudraVigilance, depend on healthcare professionals and consumers to voluntarily report adverse occurrences[8]. Although these systems can offer useful indications of possible safety concerns, they are plagued by substantial underreporting and reporting bias, as only a small portion of adverse occurrences are actually reported. Furthermore, the data gathered frequently lacks completeness, which hinders the ability to determine causality[9]. Regulatory agencies enforce periodic safety update reports, which necessitate manufacturers to regularly present concise summaries of safety data. These reports are normally compiled and evaluated at specific intervals. Nevertheless, the accuracy and thoroughness of the data presented can restrict the reliability of these reports, and they might not efficiently detect safety issues in real-time. Registries, which gather information on patients who use a certain medical product, provide a more organized approach to data collecting. However, they may have limitations in terms of their restricted focus and potential for selection bias, which can affect its applicability to a broader population[10]. In addition, conventional PMS techniques typically do not possess the capability to promptly identify and address emergent safety concerns, as they frequently rely on passive data collecting and are retrospective in nature[11]. The failure to promptly recognize adverse events can result in patients being exposed to potentially dangerous products for an extended

period of time. These constraints emphasize the necessity for more proactive and comprehensive post-market surveillance (PMS) methods that utilize real-time data and advanced analytics to guarantee the ongoing safety and effectiveness of medical products in the market[12, 13].

1.2. Introduction to AI in Healthcare:

AI technologies span a wide range of advances that imitate human cognitive functions. Machine learning (ML) is a fundamental subset of technology that allows systems to acquire knowledge from patterns in data and generate predictions without the need for explicit programming[14]. In the field of machine learning, deep learning employs neural networks with multiple layers to analyze intricate data, resulting in significant progress in the areas of image and speech recognition[15]. Natural language processing (NLP) is concerned with the interface between computers and human language[16]. It aims to improve abilities such as language translation, sentiment analysis, and conversational bots[17]. Reinforcement learning, a subfield of machine learning, entails training algorithms by repeatedly attempting different actions and learning from the outcomes in order to accomplish predetermined objectives[18]. This approach has been particularly successful in domains like as game playing and robotics[19]. Computer vision is an essential branch of artificial intelligence that enables machines to analyze and make judgments using visual data[20]. It has brought about significant advancements in various areas, such as autonomous driving and medical imaging. Together, these technologies contribute to advancements in various sectors, revolutionizing the automation of jobs, the extraction of insights from large data sets, and the facilitation of interactions between humans and machines[21]. The increasing prominence of artificial intelligence (AI) in the healthcare industry, namely in the monitoring of medical devices, is transforming patient care and enhancing clinical effectiveness[22]. Artificial intelligence (AI) algorithms are becoming more and more incorporated into medical equipment, improving their capacity to observe and analyze physiological data with exceptional precision and rapidity[23]. AI-enabled wearable devices have the capability to constantly monitor essential indicators like heart rate, blood pressure, and glucose levels. They may promptly notify patients and healthcare professionals of any potential health concerns in real-time[24]. Continuous monitoring facilitates the early identification of

diseases such as arrhythmias, hypertension, and diabetes, which in turn enables prompt therapies that can avert complications and enhance results[25].




Figure 2 Role of AI in healthcare [26]

Moreover, the utilization of AI in the monitoring of medical devices enables the practice of personalized medicine through the analysis of extensive datasets to identify trends and forecast specific health progressions[27]. The capacity to forecast is especially advantageous in the care of chronic diseases, as artificial intelligence can detect minute variations in a patient's state that may go unnoticed in conventional monitoring[28]. AI-powered gadgets alleviate the workload of healthcare personnel by automating repetitive processes and offering decision-making assistance, enabling clinicians to priorities patient care. The incorporation of artificial intelligence (AI) into the monitoring of medical devices is a notable progress towards a healthcare system that is more proactive, accurate, and efficient[29].

2. The Role of AI in Post-Market Surveillance:

Artificial intelligence (AI) significantly improves post-market surveillance by boosting the capacity to monitor, analyze, and respond to data related to the safety and effectiveness of products once they are available in the market[30]. By utilizing sophisticated machine learning algorithms, artificial intelligence can effectively analyze extensive quantities of data from various sources, including electronic health records, social media, adverse event reports, and

other forms of real-world evidence[31]. This feature allows for the detection of patterns and trends that may suggest emerging safety problems or effectiveness difficulties that would be difficult for humans to quickly identify. Furthermore, AI systems have the capability to consistently acquire knowledge and adjust, enhancing their precision and ability to make predictions as time progresses. Regulatory agencies and manufacturers can allocate their resources more effectively by assessing and ranking potential risks according to the seriousness and probability of negative events[32].



Figure 3 Steps of PMS

Furthermore, AI has the ability to enhance communication and decision-making processes by producing practical insights and visual representations. This assists stakeholders in implementing timely interventions and reducing risks. In summary, the incorporation of artificial intelligence (AI) in post-market surveillance improves the efficiency and efficacy of monitoring efforts. Additionally, it promotes better patient outcomes and safety by facilitating a proactive approach to managing risks throughout the product lifetime[33].

2.1. Data Collection and Integration

Data collection and integration are crucial in post-market surveillance to guarantee the safety and effectiveness of products after they have been released into the market. This stage is crucial for evaluating the actual performance in real-world scenarios, identifying possible problems, and providing information for regulatory choices. In this context, AI is seen as a powerful and influential factor that brings about significant changes, providing exceptional ability to manage large amounts of different types of data from various origins[34, 35]. Artificial intelligence enables the collection and examination of data from many sources, such as electronic health records, social media, wearable devices, and systems for reporting bad events[36]. The capacity to analyze both organized and unorganized data allows for the identification of patterns, trends, and irregularities that could potentially signify safety risks or problems with product performance[37]. Natural language processing (NLP) algorithms have the ability to analyze textual data, such as patient feedback, doctor notes, or internet debates, in order to extract important insights[38]. AI enhances conventional surveillance techniques by facilitating proactive monitoring and timely identification of potential hazards. Machine learning algorithms have the ability to learn from new data as it arrives, and can adjust their detection abilities over time to changing patterns of product usage and negative occurrences. By adopting a proactive strategy, regulators and manufacturers can promptly address emerging safety signals, thereby preventing widespread injury and increasing public confidence in regulatory systems[39]. AI enhances predictive analytics by using previous data and contextual elements to foresee possible safety hazards. Through the utilization of sophisticated statistical models and predictive algorithms, stakeholders have the ability to foresee and give priority to surveillance operations, thereby efficiently allocating resources to regions that pose the greatest risk. Adopting this proactive approach not only improves patient safety but also maximizes the efficient use of resources, simplifies regulatory procedures, and reduces the time it takes to take action[40]. Artificial intelligence (AI) enables the integration of data from different sources, eliminating isolated data sets and improving the overall effectiveness of monitoring initiatives. AI facilitates the smooth integration of information from clinical trials, post-market research, real-world evidence, and regulatory databases by utilizing interoperable data standards and innovative data fusion algorithms. The complete evaluation of product performance improves situational awareness, allowing regulators and manufacturers to make informed judgments based on extensive evidence[41]. AI plays a transformative role in post-market surveillance by revolutionizing the

way we monitor the safety and effectiveness of products in the real world. AI enhances public health protection by using proactive monitoring, predictive analytics, and thorough data integration. This empowers stakeholders to ensure that products fulfill their commitments while minimizing potential hazards to patients and consumers[42].

2.2. Real-Time Monitoring and Analysis

Real-time monitoring and analysis, along with artificial intelligence (AI), are crucial in post-market surveillance in different sectors, especially in healthcare and finance[43]. Real-time monitoring in the healthcare industry entails the ongoing collection and analysis of data from many sources, including electronic health records (EHRs), medical devices, and patient-reported outcomes. AI systems can subsequently analyze this enormous volume of data in real-time to identify patterns, abnormalities, and potential undesirable occurrences[44]. AI-driven systems can detect signals in post-market surveillance for medical devices and pharmaceuticals that may suggest safety concerns or product failures. Through the examination of data gathered from patient experiences, healthcare providers, and regulatory reports, artificial intelligence algorithms have the capability to promptly identify any problems. This enables regulatory authorities and manufacturers to take necessary measures, such as recalling products or making modifications to labeling and warnings[45]. In the financial sector, it is crucial to have real-time monitoring and analysis driven by artificial intelligence for post-market surveillance. This is necessary to identify fraudulent activity, market manipulation, and breaches of compliance. AI algorithms can detect fraudulent activities or regulatory infractions by analyzing transactions, market data, and news feeds, and identifying suspicious trends or abnormalities[46]. AI technologies facilitate the use of predictive analytics in post-market surveillance, enabling organizations to foresee future dangers and implement proactive actions to minimize them. For instance, in the field of healthcare, predictive analytics can be utilized to anticipate the occurrence of disease outbreaks or to pinpoint patient groups with a greater likelihood of experiencing negative reactions to specific treatments. Within the realm of finance, predictive analytics has the capability to forecast market swings or detect developing trends that could potentially influence investment strategies[47]. AI plays a crucial role in post-market surveillance by improving the efficiency, precision, and efficacy of monitoring and analytical procedures, thereby enhancing safety, compliance, and risk management in various industries. Nevertheless, it is vital to guarantee that

AI systems possess transparency, accountability, and ethical deployment in order to uphold trust and confidence in the results they produce[48].

2.3. Predictive Analytics

Predictive analytics and artificial intelligence (AI) are crucial in post-market surveillance across multiple industries, especially in healthcare, pharmaceuticals, and consumer goods. Post-market surveillance involves the ongoing monitoring of products or services after they have been made available in the market to ensure that they remain safe, effective and function well. It is essential to discover and deal with possible problems, negative occurrences, or new patterns that may not have been apparent during the testing phase before the product was released to the market[49]. AI-powered predictive analytics transforms post-market surveillance by allowing immediate monitoring and analysis of extensive data from various sources, including social media, electronic health records, product usage logs, and customer feedback. Through the utilization of sophisticated machine learning algorithms, artificial intelligence has the capability to identify patterns, anomalies, and correlations within this data, so offering significant insights on the performance of products, safety issues, and customer experiences[50]. An important function of AI in post-market surveillance is to promptly identify adverse events or safety concerns. Through ongoing analysis of data streams, artificial intelligence can detect signs that suggest potential problems related to a product or service. Early detection enables organizations to proactively take measures, such as sending safety alerts, recalling products, or adopting corrective activities, to reduce harm to consumers and safeguard public health[51]. AI enables trend research and prediction by detecting developing patterns or changes in consumer behavior, market dynamics, or regulatory tendencies. By adopting a proactive strategy, organizations may effectively predict upcoming issues, adjust their plans accordingly, and make well-informed decisions to sustain their competitiveness and ensure compliance[52]. The utilization of AI-driven predictive analytics improves the decision-making procedures by offering practical and valuable insights to many stakeholders involved in the value chain, such as regulatory bodies, manufacturers, healthcare providers, and consumers. AI can create complete risk assessments, prediction models, and recommendations that are customized to meet the individual needs and objectives of stakeholders by collecting and analyzing data from various sources[53].

3. Case Studies and Applications

Post-market surveillance is crucial for assuring the safety and effectiveness of medical products after they are made available to the public. Artificial intelligence is transforming this process by providing advanced tools for monitoring, analyzing, and interpreting extensive volumes of real-world data. Case studies and applications exemplify the various ways in which AI contributes to post-market surveillance. An important use of AI in post-market surveillance is the identification of adverse events. Conventional approaches depend on human reporting, which is time-consuming and susceptible to underreporting. Artificial intelligence algorithms have the capability to analyze diverse data sources such as electronic health records, social media, and online forums in order to quickly and completely detect potential unfavourable events. An example of this is a study that was published in JAMA Internal Medicine. The study demonstrated that an AI algorithm could accurately identify adverse medication events from electronic health records. This highlights the potential of AI to improve pharmacovigilance efforts[54]. AI enhances the process of identifying signals by examining patterns and correlations in extensive databases. Through the utilization of machine learning techniques, artificial intelligence has the capability to detect unforeseen connections between medicinal items and negative occurrences, thereby initiating additional inquiry. An instance of this is a research published in Drug Safety which showcased the ability of machine learning algorithms to discover previously unidentified drug-drug interactions through the analysis of electronic health records and claims data[55]. Another crucial element of post-market surveillance is the identification of growing safety issues. AI-driven systems have the capability to constantly monitor real-time data streams and identify indications of potential safety concerns at an early stage. This proactive strategy allows regulatory authorities and producers to promptly take measures to reduce hazards and safeguard public health. An illustration of this concept is the FDA's Sentinel Initiative, which use artificial intelligence and distributed data networks to continuously monitor the safety of medical products. This enables the prompt detection of safety signals in real-time[56].

Table 1 Summary of examples of AI in PMS[57]

| AI Application | Medical Device | Description |
|------------------------------|-----------------------------|---|
| Signal Detection | Implantable Cardiac Devices | AI algorithms are used to analyze real-world data from implanted cardiac devices to detect patterns or signals indicating potential issues such as device malfunction or adverse events. |
| Adverse Event Classification | Surgical Instruments | AI systems categorize and classify adverse events reported by healthcare providers related to the use of surgical instruments. These systems help in identifying trends and potential safety concerns more efficiently. |
| Predictive Maintenance | Imaging Equipment | AI algorithms monitor data from medical imaging devices to predict when maintenance or servicing might be required. By analyzing usage patterns and performance metrics, these systems can help prevent unexpected downtime and ensure equipment reliability. |
| Remote Monitoring | Insulin Pumps | AI-powered remote monitoring systems track real-time data from insulin pumps worn by patients with diabetes. These systems can alert healthcare providers to potential issues such as device malfunctions or abnormal glucose levels, allowing for timely intervention. |
| Compliance Monitoring | Wearable Health Monitors | AI algorithms analyze data from wearable health monitors to ensure compliance with prescribed usage instructions. These systems can detect deviations from expected usage patterns and provide feedback to users to encourage adherence to medical device protocols. |

AI improves the effectiveness and precision of adverse event reporting and analysis. Natural language processing (NLP) algorithms have the capability to extract pertinent information from unorganized sources including clinical notes, patient narratives, and social media posts. This ability helps to simplify the reporting process and enhance the quality of data. Furthermore, algorithms driven by artificial intelligence can rank and categories reported incidents according to their seriousness and probability, allowing for more efficient distribution of resources for subsequent inquiry[58].AI is transforming post-market surveillance by facilitating swift and thorough identification of adverse events, revealing concealed patterns and connections in real-world data, detecting emerging safety issues at an early stage, and improving the effectiveness

and precision of adverse event reporting and analysis. These technological developments have the potential to enhance patient safety, streamline regulatory decision-making, and cultivate trust in the healthcare system[59].

4. Advantages of Artificial Intelligence in Post-Market Surveillance

Post-market surveillance (PMS) is essential in multiple industries, especially healthcare and consumer products, to guarantee the safety, effectiveness, and quality of products once they are available in the market. Incorporating artificial intelligence (AI) into PMS procedures provides numerous benefits that can greatly improve the efficiency and effectiveness of surveillance activities[60]. First and foremost, AI allows for the automatic examination of extensive quantities of data from many sources, such as electronic health records, social media, product complaints, and adverse event reports. This feature enables the swift identification of potential safety concerns or growing patterns that may not be easily noticeable by conventional manual techniques. AI enables regulatory authorities and manufacturers to promptly and proactively address problems and safeguard public health by swiftly spotting warning signs[61]. Algorithms powered by artificial intelligence can improve the precision and uniformity of data processing in comparison to approaches driven by humans. Large datasets can be used to train machine learning models to identify patterns that indicate unfavorable occurrences or product failures. This helps reduce the chances of missing critical signals or making mistakes caused by human bias or weariness. The enhanced precision can result in more dependable decision-making and improved allocation of resources for further research and actions[62]. AI enables predictive analytics, enabling stakeholders to anticipate potential safety concerns or market patterns by analysing historical data and up-to-date information[63]. Through the utilization of predictive modelling approaches, regulators and manufacturers can proactively foresee and address hazards before they escalate into widespread issues. This approach helps to decrease the probability of expensive recalls, regulatory interventions, and harm to reputation[64].

Table 2. Advantages of AI in Post-Market Surveillance

1. Early Detection: AI algorithms can analyze large volumes of data from various sources such as social media, electronic health records, and adverse event reports to detect

potential safety issues or trends earlier than traditional methods.

2. Real-Time Monitoring: AI systems can provide real-time monitoring of adverse events and product performance, allowing for prompt interventions and risk mitigation strategies.

3. Pattern Recognition: AI can identify patterns and correlations in adverse event data that may not be immediately apparent to human analysts, enabling more accurate and timely signal detection.

4. Scalability: AI-powered surveillance systems can handle large and diverse datasets efficiently, making it possible to monitor a wide range of products and detect rare adverse events that may go unnoticed with manual methods.

5. Automation: AI algorithms can automate repetitive tasks such as data collection, cleaning, and analysis, freeing up human resources for more complex decision-making and interpretation of results.

6. Predictive Analytics: By analyzing historical data and trends, AI can help predict future safety issues or market trends, enabling proactive risk management and resource allocation.

7. Improved Accuracy: AI algorithms can reduce human error and bias in data analysis, leading to more accurate and reliable surveillance results.

8. Cost-Effectiveness: While initial implementation may require investment, AI-driven surveillance can ultimately reduce costs by streamlining processes, improving efficiency, and preventing costly safety incidents.

AI-driven automation simplifies PMS workflows by automatically doing repetitive tasks including gathering data, identifying signals, and generating reports. AI enhances operational efficiency by automating tasks and expediting procedures, allowing regulatory bodies and manufacturers to optimize the allocation of human resources. This enables them to concentrate on more valuable endeavours, such as evaluating risks, making informed decisions, and ensuring compliance with regulations[65, 66].

5. Current Challenges:

AI in post-market monitoring offers potential advantages as well as obstacles. AI may greatly improve the efficiency and effectiveness of surveillance activities by rapidly analysing large volumes of data from diverse sources, such as electronic health records, social media, and adverse event reports. Artificial intelligence algorithms have the ability to rapidly identify patterns, trends, and potential indicators of safety concerns or product malfunctions, surpassing the speed of previous manual approaches. This allows for prompt responses to reduce risks to public health. In addition, AI has the capability to enhance the precision of signal detection by reducing human biases and errors[67]. Artificial intelligence (AI) encounters certain constraints

and difficulties when it comes to post-market surveillance. An important obstacle lies in the caliber and comprehensiveness of the data. Artificial intelligence algorithms primarily depend on high-quality and standardized data in order to produce significant and valuable insights. Within the realm of post-market surveillance, the data sources available may vary in nature and may not provide a complete picture, resulting in biases and mistakes when conducting AI research. In addition, the variety of data formats and sources can present difficulties in integrating them, necessitating the use of advanced data preparation and harmonization techniques[68]. Another obstacle is in the interpretability and explainability of AI models. Although AI algorithms have the ability to discover concealed patterns and connections in data, it is essential to comprehend the process by which these models reach their findings, particularly in sectors that are significant for safety, such as healthcare. Opaque AI models, characterized by a lack of transparency in their decision-making process, give rise to questions of responsibility and trust. Regulatory agencies and healthcare professionals require interpretable AI models that offer explicit explanations of their results in order to make well-informed judgments on patient safety[69].

List 1: List of Challenges and their description

| Challenges | Description |
|-----------------------|---|
| Data Quality | Lack of standardized, structured data. Inconsistencies in data sources and formats. |
| Data Integration | Difficulty integrating data from disparate sources such as EHRs, wearables, social media, etc. |
| Privacy Concerns | Ensuring patient privacy and compliance with regulations like HIPAA while accessing sensitive data. |
| Interpretability | Understanding how AI systems arrive at their decisions, especially in highly regulated industries like healthcare or finance. |
| Bias and Fairness | Addressing biases in data and algorithms to ensure fair representation and decision-making. |
| Scalability | Scaling AI systems to handle large volumes of data and real-time monitoring across diverse platforms. |
| Regulatory Compliance | Ensuring AI systems comply with industry-specific regulations and standards. |
| Algorithm Validation | Validating AI algorithms for accuracy, reliability, and safety in real-world scenarios. |
| Resource Constraints | Limited availability of skilled personnel, computational resources, and funding for AI initiatives. |
| Adverse Event | Identifying adverse events accurately and in a timely manner from various |

If not deployed with careful consideration, AI has the potential to worsen the already existent inequalities in healthcare access and outcomes. Biases in the process of gathering data and making decisions using algorithms might have a greater influence on specific demographic groups, resulting in surveillance outcomes that are unfair and unequal. Moreover, the exorbitant expenses associated with AI technology and specialized knowledge may pose obstacles for smaller healthcare organizations or regions with limited resources, hence exacerbating the disparity in post-market surveillance capacities[69]. The employment of AI in post-market surveillance raises significant ethical problems. Privacy risks emerge while examining delicate patient data, necessitating strong data safeguarding procedures and adherence to standards such as the Health Insurance Portability and Accountability Act (HIPAA). Furthermore, inquiries around data ownership, transparency in algorithms, and the possibility of unexpected outcomes emphasize the necessity for ethical frameworks and governance procedures to direct the appropriate advancement and implementation of AI in surveillance operations[69].

Future Perspectives:

AI is set to transform the way we oversee the safety, effectiveness, and performance of medical products and devices in the field of post-market monitoring. An effective approach is to employ sophisticated natural language processing (NLP) methods to examine extensive quantities of unorganized data from many sources, including social media, electronic health records, and medical literature. Through the utilization of artificial intelligence, regulatory agencies and healthcare organizations can rapidly discover new safety concerns, detect adverse occurrences, and track trends in the real-world performance of products[70, 71]. The utilization of AI-driven predictive analytics might augment proactive surveillance endeavors by predicting potential safety concerns prior to their escalation into widespread issues. Machine learning algorithms have the capability to examine past data in order to discover patterns and connections. This allows for the early detection of signals that could potentially suggest safety hazards or product malfunctions. By adopting a proactive strategy, regulatory agencies and manufacturers can proactively take measures, such as issuing warnings, recalls, or implementing targeted interventions, to prevent potential harm to patients[72]. The incorporation of artificial

intelligence (AI) with emerging technologies such as Internet of Things (IoT) devices and wearable sensors shows great potential for improving post-market surveillance capabilities. These integrated systems can consistently gather and provide live data on patient results, device utilization, and ambient conditions, offering a thorough comprehension of product effectiveness in various real-life situations. Artificial intelligence systems can process this large amount of data to identify irregularities, forecast equipment failures, and evaluate the consequences of interventions, facilitating prompt actions and ongoing enhancement of product reliability and effectiveness[73]. The emergence of AI-powered pharmacovigilance systems allows for automated identification and examination of signals by extracting information from electronic health records, clinical trial data, and reports of spontaneous adverse events. These platforms utilize sophisticated algorithms to prioritize signals based on their clinical significance, enabling regulators and healthcare practitioners to allocate resources towards studying the most crucial safety concerns. AI improves the efficiency of post-market monitoring activities by simplifying the signal detection process and lowering the need for manual review, resulting in speedier decision-making[74]. The utilization of AI in post-market surveillance goes beyond the scope of traditional pharmacovigilance and includes a wider range of healthcare measures, such as personalized medicine and precision public health programs. Artificial intelligence algorithms have the capability to examine individual patient characteristics, genetic information, and real-life results in order to customize treatment approaches and enhance therapeutic results while reducing the occurrence of negative occurrences[75]. This personalized approach not only improves patient safety but also allows for more effective allocation of resources and delivery of treatment[76].

Conclusions:

In the realm of post-market surveillance, AI offers a transformative approach to monitoring the safety and efficacy of medical products once they are on the market. Through advanced algorithms and machine learning techniques, AI enables the analysis of vast amounts of real-world data, including electronic health records, patient reports, and adverse event databases. This allows for the early detection of potential safety issues, identification of patterns, and trends that may indicate previously unrecognized risks, and the ability to predict adverse events before they escalate. Moreover, AI can facilitate the rapid assessment of safety signals and provide valuable

insights into the effectiveness of risk mitigation strategies. By automating and streamlining many aspects of post-market surveillance, AI has the potential to enhance the efficiency and effectiveness of regulatory oversight, improve patient safety, and ultimately contribute to better public health outcomes. However, the widespread adoption of AI in post-market surveillance also raises important ethical, regulatory, and technical challenges that must be addressed. These include issues related to data privacy and security, transparency and interpretability of AI algorithms, bias and fairness in data analysis, and the need for robust validation and regulatory frameworks. Despite these challenges, the integration of AI into post-market surveillance holds great promise for advancing the field and ensuring the ongoing safety and effectiveness of medical products in the real world.

Disclaimer (Artificial intelligence)

Option 1:

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

Option 2:

Author(s) hereby declare that generative AI technologies such as Large Language Models, etc have been used during writing or editing of manuscripts. This explanation will include the name, version, model, and source of the generative AI technology and as well as all input prompts provided to the generative AI technology

Details of the AI usage are given below:

- 1.
- 2.
- 3.

References

1. Watari R, Matsuda A, Ohnishi S, Hasegawa H (2019) Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting μ -opioid receptor antagonist. *Drug Metab Pharmacokinet* 34(2):126–133. <https://doi.org/10.1016/j.dmpk.2018.12.002>.doi:10.1016/j.dmpk.2018.12.002.

2. Coluzzi, F., M.S. Scerpa, and J. Pergolizzi, *Naldemedine: A New Option for OIBD*. J Pain Res, 2020. **13**.
3. Farmer, A.D., et al., *Pathophysiology and management of opioid-induced constipation: European expert consensus statement*. United European Gastroenterol J, 2019. **7**.
4. Hale, M., et al., *Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, Phase 3, double-blind, randomised, parallel-group trials*. Lancet Gastroenterol Hepatol, 2017. **2**.
5. Kanemasa, T., et al., *Pharmacologic effects of naldemedine, a peripherally acting μ -opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation*. Neurogastroenterol Motil., 2019. **31**.
6. Katakami, N., et al., *Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer*. J Clin Oncol, 2017. **3**.
7. Katakami, N., et al., *Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer*. Ann Oncol, 2018. **29**.
8. Katakami, N., et al., *Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer*. J Clin Oncol, 2017. **35**.
9. Saito, Y., et al., *Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label phase III studies*. J Pain Res, 2019. **12**.
10. Webster, L.R., T. Yamada, and J.C. Arjona Ferreira, *A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain*. Pain Med, 2017. **18**.
11. Viscusi, E.R., *Clinical Overview and Considerations for the Management of Opioid-induced Constipation in Patients With Chronic Noncancer Pain*. Clin J Pain, 2019. **35**.
12. Viscusi, E.R. and A.R. Viscusi, *Blood-brain barrier: mechanisms governing permeability and interaction with peripherally acting μ -opioid receptor antagonists*. Reg Anesth Pain Med, 2020. **45**.
13. Webster, L.R., et al., *Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study*. Pain, 2018. **159**.
14. Brahmam, S., Jain, L.C. (eds.): *Advanced Computational Intelligence Paradigms in Healthcare 6: Virtual Reality in Psychotherapy, Rehabilitation, and Assessment*. Springer, Heidelberg (2011).
15. Bichindaritz, I.S., et al. (eds.): *Advanced Computational Intelligence Paradigms in Healthcare 4: Advanced Methodologies*. Springer, Heidelberg (2010).
16. Brahmam, S., Jain, L.C. (eds.): *Advanced Computational Intelligence Paradigms in Healthcare 5: Intelligent Decision Support Systems*. Springer, Heidelberg (2010).
17. Vaidya, S., et al. (eds.): *Advanced Computational Intelligence Paradigms in Healthcare 2*. Springer, Heidelberg (2008).
18. Sardo, M., et al. (eds.): *Advanced Computational Intelligence Paradigms in Healthcare 3*. Springer, Heidelberg (2008).
19. Yoshida, H., et al. (eds.): *Advanced Computational Intelligence Paradigms in Healthcare 1*. Springer, Heidelberg (2007).
20. Ichalkaranje, N., et al. (eds.): *Intelligent Paradigms for Assistive and Preventive Healthcare*. Springer, Heidelberg (2006).
21. Silverman, B., et al. (eds.): *Intelligent Paradigms in Healthcare Enterprises*. Springer, Heidelberg (2005).

22. Jain, A., et al. (eds.): *Artificial Intelligence Techniques in Breast Cancer Diagnosis and Prognosis*. World Scientific (2000).
23. Chen, Y., et al. (eds.): *Innovation in medicine and healthcare 2021*. In: *Proceedings of the KES-InMed 2021 Conference*. Springer, Germany (2021).
24. Chen, Y., et al. (eds.): *Innovation in medicine and healthcare 2022*. In: *Proceedings of the KES-InMed 2022 Conference*. Springer, Germany (2022).
25. Chen, et al. (eds.): *Innovation in medicine and healthcare 2017*. In: *Proceedings of the KES-InMed 2017 Conference*. Springer, Germany (2017).
26. Badnjevic, A., *Evidence-based maintenance of medical devices: current shortage and pathway towards solution*. *Technol Health Care*, 2023. **31**.
27. Chen, Y., et al. (eds.): *Innovation in medicine and healthcare 2016*. In: *Proceedings of the KES-InMed 2016 Conference*. Springer, Germany (2016).
28. Chen, Y., et al. (eds.): *Innovation in medicine and healthcare 2015*. In *Proceedings of the KES-InMed 2015 Conference*. Springer, Germany (2015).
29. Grana, M., et al. (eds.): *Innovation in Medicine and Healthcare*. IOS Press (2014).
30. Holsapple, C., Whinston, A., Whinston, A.: *Business Expert Systems*. McGraw-Hill (1987).
31. Leondes, C.T.: *Expert Systems: The Technology of Knowledge Management and Decision Making for the 21st Century*, pp. 1–22 (2002).
32. Xu, L., Jiang, L., Qin, C., Wang, Z., Du, D.: *How images inspire poems: generating classical Chinese poetry from images with memory networks*. In: *Proceedings of the Thirty-Second AAAI Conference on Artificial Intelligence and Thirtieth Innovative Applications of Artificial Intelligence Conference and Eight AAAI Symposium on Educational Advances in Artificial Intelligence*, vol. 689, pp. 5618–5625 (2018).
33. Shortliffe, E.: *Computer-Based Medical Consultations: MYCIN*. Elsevier (1976).
34. Belciug, S., Gorunescu, F.: *Era of intelligent systems in healthcare*. In: Belciug, S., Gorunescu, F. (eds.) *Intelligent Decision Support Systems: A Journey to Smarter Healthcare*. Springer, Heidelberg (2020).
35. Sim, I., Gorman, P., Greenes, R.A., et al.: *Clinical decision support systems for the practice of evidence-based medicine*. *J. Am. Med. Inform. Assoc.* 8(6), 527–534 (2001).
36. Basilico, J. (2019). *Netflix research*. Retrieved from <https://research.netflix.com/research-area/machine-learning>.
37. Blackwood, A. (2021). *Data visualisation: Basics & trends*. Retrieved from <https://blog.iotechnologies.com/data-visualization-trends>.
38. Buuck, B. (2022). *The operational data store (ODS) vs data warehouse*. Retrieved from <https://streamsets.com/blog/operational-data-stores-ods-data-warehouses>.
39. Clayton, T. (2019). *The difference between implicit and explicit data for business*. Retrieved from <https://blog.mirumee.com/the-difference-between-implicit-and-explicit-data-for-business-351f70ff3fbf>.
40. Cubeware GmbH. (2022). *Structured data: Definition, examples, and comparison*. Retrieved from <https://www.linkedin.com/pulse/structured-data-definition-examples-comparison-cubeware-gmbh>.
41. CX Trend. (2022). *The Zendesk customer experience trends report 2022*. Retrieved from <https://www.zendesk.com/customer-experience-trends>.
42. David, D. (2021). *AI vs ML – What's the difference between artificial intelligence and machine learning?* Retrieved from <https://www.freecodecamp.org/news/ai-vs-ml-whats-the-difference>.
43. Grieve, P. (2022). *The importance of providing personalized service in 2022*. Retrieved from <https://www.zendesk.com/in/blog/start-providing-personalized-customer-service/#georedirect>.

44. Han, M. (2021). *Analysis of the public's intention to use the government's artificial intelligence (AI)-based services: Focusing on public values and extended technology acceptance model*. *The Journal of the Korea Contents Association*, 21(8), 388–402.
45. Hyken, S. (2017). *Personalized customer experience increases revenue and loyalty*. Retrieved from <https://www.forbes.com/sites/shephyken/2017/10/29/personalized-customer-experience-increases-revenue-and-loyalty/?sh=62f148054bd6>.
46. Hyperight. (2021). *Deep brew: Transforming Starbucks into an AI & data-driven company*. Hyperight.com. <https://hyperight.com/deep-brew-transforming-starbucks-into-a-data-driven-company>.
47. IBM. (2021). *Structured vs. unstructured data: What's the difference?* Retrieved from <https://www.ibm.com/cloud/blog/structured-vs-unstructured-data>.
48. IBM Cloud Education. (2021). *What is data visualization?* Retrieved from <https://www.ibm.com/cloud/learn/data-visualization>.
49. Kostusev, D. (2018). *Personalization in sales: Why it matters and how to achieve it*. Retrieved from <https://www.forbes.com/sites/forbesbusinessdevelopmentcouncil/2018/06/11/personalization-in-sales-why-it-matters-and-how-to-achieve-it/?sh=5a0ffd819127>.
50. Kotsiantis, S. (2006). *Association rules mining: A recent overview*. Retrieved from <https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.103.6295&rep=rep1&type=pdf>.
51. Krishnan, S., Franklin, M. J., Goldberg, K., Wang, J., & Wu, E. (2016). *Active clean: An interactive data cleaning framework for modern machine learning*. In *Proceedings of the 2016 international conference on management of data*. <https://doi.org/10.1145/2882903.2899409>.
52. Kumar, V., & Khosla, C. (2018). *Data Cleaning-A thorough analysis and survey on unstructured data*. In *2018 8th international conference on cloud computing, data science & engineering (Confluence)*. <https://doi.org/10.1109/confluence.2018.8442950>.
53. Lenzerini, M. (2002). *Data integration*. *Proceedings of the twenty-first ACM SIGMOD-SIGACT-SIGART symposium on principles of database systems - PODS '02*. <https://doi.org/10.1145/543613.543644>.
54. Chaudhry, H. A. H., Renzulli, R., Perlo, D., Santinelli, F., Tibaldi, S., Cristiano, C., Grosso, M., Limerutti, G., Fiandrotti, A., Grangetto, M., et al. (2022). *UniToChest: A lung image dataset for segmentation of cancerous nodules on CT scans*. In: *Image analysis and processing-ICIAP 2022: 21st international conference, Lecce, Italy, May 23–27, 2022, Proceedings, Part I* (pp. 185–196). Springer.
55. De Streel, A., Bibal, A., Frénay, B., Lognoul, M. (2020). *Explaining the black box: When law controls AI*. CERRE.
56. Tietjen, D., von Woedtker, N., Schwind, E. (2021). *Artificial intelligence act (AIA)—Legal uncertainty for medical device manufacturers*.
57. Badnjević, A., L.G. Pokvić, and Z. Džemić, *Risks of emergency use authorizations for medical products during outbreak situations: a COVID-19 case study*. *BioMed Eng OnLine*, 2020. **19**.
58. Amantea, I.A., et al., *Adopting assistive technologies in healthcare processes: A chatbot for patients with amyotrophic lateral sclerosis*, in *Italian forum of ambient assisted living*. 2022, Springer.
59. Amantea, I.A., et al., *A process mining application for the analysis of hospital-at-home admissions*. *Studies in Health Technology and Informatics*, 2020. **270**.
60. Ebers, M., *Standardizing AI-the case of the European commission's proposal for an artificial intelligence act*, in *The Cambridge handbook of artificial intelligence: Global perspectives on law and ethics*. 2021, Cambridge University Press.

61. Ebers, M., et al., *The European commission's proposal for an artificial intelligence act—A critical assessment by members of the robotics and AI law society (RAILS)*. Multidisciplinary Scientific Journal, 2021. **4**.
 62. Floridi, L., et al., *AI4People—An ethical framework for a good AI society: Opportunities, risks, principles, and recommendations*. Minds and Machines, 2018. **28**.
 63. Jin, Y.H., et al., *A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)*. Military Medical Research, 2020. **7**.
 64. Marchi, F., et al., *E-health solutions for amyotrophic lateral sclerosis patients: A chatbot for dietary monitoring*. Journal of the Neurological Sciences, 2021. **429**.
 65. Minssen, T., M. Mimler, and V. Mak, *When does stand-alone software qualify as a medical device in the European Union?—The CJEU's decision in Snitem and what it implies for the next generation of medical devices*. Medical Law Review, 2020. **28**.
 66. Munoz-Gama, J., et al., *Process mining for healthcare: Characteristics and challenges*. Journal of Biomedical Informatics, 2022. **127**.
 67. Palmieri, S., P. Walraet, and T. Goffin, *Inevitable influences: AI-based medical devices at the intersection of medical devices regulation and the proposal for AI regulation*. European Journal of Health Law, 2021. **28**.
 68. Veale, M. and F.Z. Borgesius, *Demystifying the draft EU artificial intelligence act—analysing the good, the bad, and the unclear elements of the proposed approach*. Computer Law Review International, 2021. **22**.
 69. Zhang, X., et al., *Prediction of emergency department hospital admission based on natural language processing and neural networks*. Methods of Information in Medicine, 2017. **56**.
 70. Senbekov M et al (2020) *The recent progress and applications of digital technologies in healthcare: a review*. Int J Telemed Appl.
 71. *Effective post-market surveillance: Understanding and conducting vigilance and post-market clinical follow-up [Pamphlet]*. BSI Standards Ltd., London (UK) (2014).
 72. *Food and Drug Administration (FDA) [Internet]*. Food and Drug Administration, Silver Spring (MA).
 73. EUDAMED Database. <https://ec.europa.eu/tools/eudamed/eudamed>.
 74. MEDSun. <https://www.fda.gov/medical-devices/medical-device-safety/medsun-medical-product-safety-network>.
 75. Badnjević A et al (2022) *Post-market surveillance of medical devices: a review*. Technol Health Care 30(6):1315–1329.
 76. Badnjević A, Pokvić LG, Hasičić M, Bandić L, Mašetić Z, Kovačević Ž, Kevrić J, Pecchia L (2019) *Evidence-based clinical engineering: machine learning algorithms for prediction of defibrillator performance*. Biomed Sig Process Control 54:101629.
- 77Chinzei K, Shimizu A, Mori K, Harada K, Takeda H, Hashizume M, Ishizuka M, Kato N, Kawamori R, Kyo S, Nagata K. Regulatory science on AI-based medical devices and systems. Advanced Biomedical Engineering. 2018;7:118-23.
- 78 Benjamens S, Dhunnoo P, Meskó B. The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database. NPJ digital medicine. 2020 Sep 11;3(1):118.

79 Joshi G, Jain A, Araveeti SR, Adhikari S, Garg H, Bhandari M. FDA-Approved Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices: An Updated Landscape. *Electronics*. 2024 Jan 24;13(3):498.

80 Gerke S. Health AI for good rather than evil? The need for a new regulatory framework for AI-based medical devices. *Yale J. Health Pol'y L. & Ethics*. 2021;20:432.

UNDER PEER REVIEW